Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA Methylation Sequencing for Multiple Myeloma Minimal Residual Disease Detection and Clonal Evolution Monitoring

NCT05578625 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT05578625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05578625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA Methylation Sequencing for Multiple Myeloma Minimal Residual Disease Detection and Clonal Evolution Monitoring
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2022
Completion date
June 30, 2025
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma